Author: Hossam Elgnainy

WHO consolidated operational handbook on tuberculosis: module 4: treatment and care https://www.who.int/publications/i/item/9789240108141

WHO consolidated guidelines on tuberculosis: module 4: treatment and care https://www.who.int/publications/i/item/9789240107243

Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. https://pubmed.ncbi.nlm.nih.gov/19643501/

WHO recommends initial adjuvant corticosteroid therapy in children and adolescents with tuberculosis meningitis with either: dexamethasone 0.3-0.6 mg/kg/day initially for about 4 weeks then tapered...

No, antiepileptic drugs (AEDs) are not used routinely in all pediatric road traffic accident (RTA) cases. When are Antiepileptic Drugs Indicated? Prophylactic AEDs are reserved for children at high...

Maintain insulin infusion until resolution of acidosis, which typically takes longer than normalization of blood glucose levels, and is indicated by pH > 7.3, serum bicarbonate > 18 mEq/L (18 mmol/L),...

No, azithromycin should not be used solely as an immunomodulator for acute chest infections in infants under 1 year. why: ​Lack of Clinical Benefit: Studies show its anti-inflammatory properties do...

Why Azithromycin is Not Routine ​Viral Dominance: The vast majority of lower respiratory tract infections in infants under 1 year (such as bronchiolitis) are viral in origin, most commonly Respiratory...

No, azithromycin is not routinely used as a first-line or empirical treatment for chest infections in infants less than 1 year of age. Its use in this age group is reserved for specific, confirmed, or...

Can you please, state your question?

Nebulized furosemide doses of 1 or 2 mg/kg may be effective in improving pulmonary mechanics in preterm infants with BPD, but recommendations on frequency and duration of therapy are limited. 1 mg/kg...

There is no single comprehensive source for pediatric ECMO drug dosing, as evidence is limited and varies by drug, age, and circuit type. The best approach is to combine data from key reviews (e.g., Raffaeli...